Blastic Plasmacytoid Dendritic Cell Neoplasm: A Single-Center Experience. Clinical Characterization, Mutational Landscape, and Clinical Outcome of Patients Undergoing Hematopoietic Stem Cell Transplantation Intensive Therapy.
Actas Dermosifiliogr
; 2024 Jun 07.
Article
en En, Es
| MEDLINE
| ID: mdl-38852841
ABSTRACT
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematodermic neoplasm usually involving the skin. In this retrospective case series, 10 cases of BPDCN were identified, 90% of which had skin involvement and exhibited predominantly violaceous nodules and/or bruise-like plaques. Skin lesions showed diffuse or nodular dermal-based infiltrates of intermediate sized blasts with a grenz zone. Tumor immunophenotyping was CD4(+), CD56(+), CD123(+) and CD303(+). The most frequently mutated genes according to targeted next-generation sequencing were TET2 (3/7) and NRAS (2/7). Multiagent chemotherapy (CT) was administered as first-line therapy, and a total of 5 patients underwent allogenic hematopoietic stem cell transplantation (allo-HSCT). Better outcomes were observed in younger patients and those treated with acute lymphoblastic leukemia (ALL)-like CT followed by allo-HSCT. This study shows the clinical range of cutaneous lesions of BPDCN. Despite the absence of a gold standard therapy, patients treated with myeloablative intensive regimens and allo-HSCT seems to have a more favorable prognosis.
Blastic plasmacytoid dendritic cell neoplasm; Cutaneous lymphomas; Hematologic neoplasm; Hematopoietic stem cell transplantation; Linfoma cutáneo; Neoplasia blástica de células dendríticas plasmocitoides; Neoplasia hematológica; Next-generation sequencing; Trasplante alogénico de progenitores hematopoyéticos
Texto completo:
1
Banco de datos:
MEDLINE
Idioma:
En
/
Es
Año:
2024
Tipo del documento:
Article